161 related articles for article (PubMed ID: 33163031)
21. Polycystic ovaries and associated clinical and biochemical features in young women.
Michelmore KF; Balen AH; Dunger DB; Vessey MP
Clin Endocrinol (Oxf); 1999 Dec; 51(6):779-86. PubMed ID: 10619984
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity of plasma insulin levels in obese and non-obese women with functional hyperandrogenism.
Sütterlin M; Steck T
Gynecol Endocrinol; 1995 Mar; 9(1):37-44. PubMed ID: 7793298
[TBL] [Abstract][Full Text] [Related]
23. Elevated anti-Mullerian hormone in lean women may not indicate polycystic ovarian syndrome.
Bradbury RA; Lee P; Smith HC
Aust N Z J Obstet Gynaecol; 2017 Oct; 57(5):552-557. PubMed ID: 28597496
[TBL] [Abstract][Full Text] [Related]
24. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
25. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
26. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
27. Relationship between early follicular serum estrone level and other hormonal or ultrasonographic parameters in women with polycystic ovary syndrome.
Chun S
Gynecol Endocrinol; 2020 Feb; 36(2):143-147. PubMed ID: 31242783
[TBL] [Abstract][Full Text] [Related]
28. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome.
Ates S; Aydın S; Ozcan P; Soyman Z; Gokmen Karasu AF; Sevket O
J Obstet Gynaecol; 2018 Feb; 38(2):236-240. PubMed ID: 28920502
[TBL] [Abstract][Full Text] [Related]
29. Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?
Yang S; Wang Q; Huang W; Song Y; Feng G; Zhou L; Tan J
Gynecol Endocrinol; 2016; 32(1):38-41. PubMed ID: 26291816
[TBL] [Abstract][Full Text] [Related]
30. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
Chen F; Chen M; Zhang W; Yin H; Chen G; Huang Q; Yang X; Chen L; Lin C; Yin G
J Ovarian Res; 2021 Feb; 14(1):32. PubMed ID: 33583431
[TBL] [Abstract][Full Text] [Related]
32. Transvaginal ultrasound imaging, histopathology and endocrinopathy in patients with polycystic ovarian syndrome.
Takahashi K; Eda Y; Abu-Musa A; Okada S; Yoshino K; Kitao M
Hum Reprod; 1994 Jul; 9(7):1231-6. PubMed ID: 7962423
[TBL] [Abstract][Full Text] [Related]
33. Sonographic parameters and hormonal status in lean and obese women with polycystic ovary syndrome.
Sengos C; Andreakos C; Iatrakis G
Clin Exp Obstet Gynecol; 2000; 27(1):35-8. PubMed ID: 10758797
[TBL] [Abstract][Full Text] [Related]
34. [Plasma renin and aldosterone levels in obese and non-obese women with polycystic ovary syndrome].
Mejia-Montilla J; Reyna-Villasmil E; Torres-Cepeda D; Santos-Bolívar J; Reyna-Villasmil N; Bravo-Henríquez A
Endocrinol Nutr; 2012 Jan; 59(1):21-7. PubMed ID: 22115703
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
37. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.
Legro RS; Chiu P; Kunselman AR; Bentley CM; Dodson WC; Dunaif A
J Clin Endocrinol Metab; 2005 May; 90(5):2571-9. PubMed ID: 15713728
[TBL] [Abstract][Full Text] [Related]
38. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B.
Chu MC; Carmina E; Wang J; Lobo RA
Fertil Steril; 2005 Dec; 84(6):1685-8. PubMed ID: 16359965
[TBL] [Abstract][Full Text] [Related]
39. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.
Panidis D; Tziomalos K; Macut D; Delkos D; Betsas G; Misichronis G; Katsikis I
Fertil Steril; 2012 Feb; 97(2):494-500. PubMed ID: 22192350
[TBL] [Abstract][Full Text] [Related]
40. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
